Actionable news
All posts from Actionable news
Actionable news in NXTM: NxStage Medical, Inc.,

Top Analyst Upgrades and Downgrades: FibroGen, Foot Locker, GW Pharma, LendingClub, Lockheed Martin, Tesla, UPS and More

Stocks were indicated marginally lower on Tuesday, but the Dow went above 22,100 and has been up 10 days in a row. August is also supposed to be a bad month for the markets historically. And even though this bull market is now well over eight years old, the prevailing theme is that investors keep finding new reasons to buy stocks after each single sell-off. Investors are also searching for new investing and trading ideas.

24/7 Wall St. reviews dozens of analyst research reports each day of the week to find new investing and trading ideas for our readers. Some analyst reports cover stocks to buy and some cover stocks to sell or to avoid.

Additional color and commentary has been added on most of the daily analyst calls. Consensus analyst price target data are from the Thomson Reuters sell-side research service.

These were the top analyst upgrades, downgrades and other research calls from Tuesday, August 8, 2017.

FibroGen Inc. (NASDAQ: FGEN) was just included in a Jefferies pool of top near-term catalysts for upside, and now Jefferies has reiterated its Buy rating and raised its target on FibroGen to $75 from $50 (versus a $33.40 prior close) now that it reported stat-sig-positive Phase 2 IPF lung data for 2nd drug FG-3019 and it believes that significant value creation should occur now. Stifel already had a Buy rating and $38 target, but the firm just raised its target to $80 on this news. FibroGen shares were last seen trading up 61% at $53.75, well above the prior high of $35.85.

Foot Locker Inc. (NYSE: FL) was raised to Overweight from Equal Weight with a $65 price target (versus a $48.84 close) at Morgan Stanley. It has a 52-week trading range of $44.59 to $79.43 and a consensus analyst price target of .21. Shares were indicated up 3.2% at $50.40 on Tuesday morning after the call.

GW Pharmaceuticals PLC (NASDAQ: GWPH)...